Wait for it--Shire could finally announce $32.5B Baxalta deal by Monday

Could Shire's ($SHPG) months-long pursuit of Baxalta ($BXLT) finally be coming to a close? That's the word from Reuters, which says the Dublin drugmaker is preparing to announce its acquisition--valued at about $32.5 billion--as early as Monday. The $48-per-share deal's cash component--which reportedly held things up as Shire sought a way to avoid taking on a tax liability related to Baxalta's summer spinoff from Baxter ($BAX)--will come in just below $20 per share, the news service reports. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.